

Pediatric CIRB Meeting Agenda

May 14, 2026

I. Amendment Review

AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (Version Date 04/01/26)

II. Amendment Review

AALL1821, A Phase 2 Study of Blinatumomab (NSC# 765986, IND #147294) in Combination with Nivolumab (NSC# 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to <31 Years Old with First Relapse (Version Date 03/20/26)

III. Amendment Review

ACNS2321, A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas (Version Date 04/01/26)

IV. Amendment Review

ALTE2131, Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer (Version Date 04/24/26)

V. Amendment Review

ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a γ -Secretase Inhibitor, Nirogacestat (PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors (Version Date 03/18/26)

VI. Amendment Review

PED-CITN-02, GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure (Version Date 03/13/26)

VII. Amendment Review

PEPN2415, A Phase I study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AZD1390 (NSC# 852149, IND# 172675) when combined with focal radiation in pediatric patients with High Grade Glioma (Version Date 03/17/26)

VIII. Continuing Review

AALL2131, An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia (Version Date 02/27/26)

IX. Continuing Review

AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma (Version Date 10/16/25)

X. Continuing Review

ANBL2131, A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (Version Date 06/25/25)

XI. Continuing Review

ARAR2221, Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) (Version Date 07/24/25)
